Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...
CNBC

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a long ...
Time

Vertex Pharmaceuticals

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.
Seeking Alpha

Vertex Pharmaceuticals: Strategically Positioning For Future Success

Vertex Pharmaceuticals showed strong Q2 2023 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and U.S. growth. Management outlined growth initiatives in various ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...